Recombinant Human TRIM72 protein, MYC/DDK-tagged

Cat.No. : TRIM72-12H
Product Overview : Recombinant Human TRIM72 fused with MYC/DDK tag at C-terminal was expressed in HEK293.
Availability July 05, 2025
Unit
Price
Qty
  • Specification
  • Gene Information
  • Related Products
  • Citation
  • Download
Species : Human
Source : HEK293
Tag : DDK&Myc
Form : 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol.
Molecular Mass : 52.6 kDa
Concentration : >50 ug/mL as determined by microplate BCA method
Publications :
MG53 anchored by dysferlin to cell membrane reduces hepatocyte apoptosis which induced by ischaemia/reperfusion injury in vivo and in vitro. (2017)
Gene Name TRIM72 tripartite motif containing 72 [ Homo sapiens ]
Official Symbol TRIM72
Synonyms TRIM72; tripartite motif containing 72; tripartite motif-containing protein 72; mitsugumin-53; tripartite motif-containing 72; MG53;
Gene ID 493829
mRNA Refseq NM_001008274
Protein Refseq NP_001008275
MIM 613288
UniProt ID Q6ZMU5
Chromosome Location 16p11.2
Function metal ion binding; phosphatidylserine binding; zinc ion binding;

MG53 anchored by dysferlin to cell membrane reduces hepatocyte apoptosis which induced by ischaemia/reperfusion injury in vivo and in vitro

Journal: Journal of Cellular and Molecular Medicine    PubMed ID: 28401647    Data: 2017/4/12

Authors: Weifeng Yao, Haobo Li, Ziqing Hei

Article Snippet:Some of the rats received recombinant human MG53 protein (rhMG53, i.v., 5 mg/kg) or vehicle (0.9% sterile saline) 2 hrs before surgery.Some of the rats received recombinant human MG53 protein (rhMG53, i.v., 5 mg/kg) or vehicle (0.9% sterile saline) 2 hrs before surgery.. The rhMG53 protein was obtained from Creative BioMart Company (Cat#. TRIM72‐156H).. DNA sequence encoding the human MG53 (Gene ID: 493829) was fused with a polyhistidine tag at the C‐terminus.DNA sequence encoding the human MG53 (Gene ID: 493829) was fused with a polyhistidine tag at the C‐terminus.

MG53 administration reduced hepatic injury and oxidative stress during ischaemia/reperfusion. Rats were subjected to HIR or sham operation with or without administration of rhMG53 via caudal vein and then samples were collected after liver reperfusion for 6 and 24 hrs. ( A and B ) Haematoxylin and eosin (H&E)‐stained sections of livers (×200) and Suzuki's scores; ( C ) serum aspartate aminotransferase (AST) level; ( D ) serum alanine aspartate aminotransferase (ALT) level; ( E and F ) reactive oxygen species (ROS) levels assessed using fluorescence microscopy following the changes in immunofluorescence staining (×200) of liver dihydroethidium (DHE) (red). ( G and H ) Immunohistochemical staining (×200) of liver 4‐hydroxynonenal (4‐HNE) and density analysis. ( I ) Liver antioxidant enzyme superoxide dismutase (SOD) activity; ( J ) liver oxidative stress marker 15‐F2t‐isoprostane level. Date are mean ± SEM, n = 8/group, ** P < 0.01. HIR, hepatic ischaemia/reperfusion; rhMG53, recombinant human MG53 protein.

MG53 administration reduced hepatic injury and oxidative stress during ischaemia/reperfusion. Rats were subjected to HIR or sham operation with or without administration of rhMG53 via caudal vein and then samples were collected after liver reperfusion for 6 and 24 hrs. ( A and B ) Haematoxylin and eosin (H&E)‐stained sections of livers (×200) and Suzuki's scores; ( C ) serum aspartate aminotransferase (AST) level; ( D ) serum alanine aspartate aminotransferase (ALT) level; ( E and F ) reactive oxygen species (ROS) levels assessed using fluorescence microscopy following the changes in immunofluorescence staining (×200) of liver dihydroethidium (DHE) (red). ( G and H ) Immunohistochemical staining (×200) of liver 4‐hydroxynonenal (4‐HNE) and density analysis. ( I ) Liver antioxidant enzyme superoxide dismutase (SOD) activity; ( J ) liver oxidative stress marker 15‐F2t‐isoprostane level. Date are mean ± SEM, n = 8/group, ** P < 0.01. HIR, hepatic ischaemia/reperfusion; rhMG53, recombinant human MG53 protein.

Protective effects of rhMG53 were related to hepatic apoptosis inhibition. Rats were subjected to HIR or sham operation with or without administration of rhMG53 via caudal vein and then samples were collected after liver reperfusion for 6 and 24 hrs. ( A ) Terminal deoxynucleotidyl transferase‐mediated nick‐end labelling (TUNEL) staining (×200) of liver; ( B ) Bax/Bcl‐2, caspase 3/cleaved caspase 3 and cytochrome c (Cyto‐ c ) protein expression; ( C ) percentage of TUNEL‐positive cells; ( D and F ) density analysis of Bax/Bcl‐2, caspase 3/cleaved caspase 3 and cytochrome c (Cyto‐ c ) protein expression. Date are mean ± SEM, n = 8/group, ** P < 0.01. HIR, hepatic ischaemia/reperfusion; rhMG53, recombinant human MG53 protein.

Protective effects of rhMG53 were related to hepatic apoptosis inhibition. Rats were subjected to HIR or sham operation with or without administration of rhMG53 via caudal vein and then samples were collected after liver reperfusion for 6 and 24 hrs. ( A ) Terminal deoxynucleotidyl transferase‐mediated nick‐end labelling (TUNEL) staining (×200) of liver; ( B ) Bax/Bcl‐2, caspase 3/cleaved caspase 3 and cytochrome c (Cyto‐ c ) protein expression; ( C ) percentage of TUNEL‐positive cells; ( D and F ) density analysis of Bax/Bcl‐2, caspase 3/cleaved caspase 3 and cytochrome c (Cyto‐ c ) protein expression. Date are mean ± SEM, n = 8/group, ** P < 0.01. HIR, hepatic ischaemia/reperfusion; rhMG53, recombinant human MG53 protein.

rhMG53 attenuated hepatic ischaemia/reperfusion injury via interaction with dysferlin. Rats were subjected to HIR or sham operation with or without administration of rhMG53 via caudal vein and then samples were collected after liver reperfusion for 6 and 24 hrs. ( A and B ) Immunofluorescence staining (×400) of liver dysferlin (DYSF) (Red) and nucleus (blue) and density analysis; ( C ) Western blot assay on liver dysferlin and MG53 at 6 hrs after reperfusion. ( D ) Immunoprecipitation assay of dysferlin/MG53 at 6 hrs after reperfusion. Date are mean ± SEM, n = 8/group, * P < 0.05, ** P < 0.01. HIR, hepatic ischaemia/reperfusion; rhMG53, recombinant human MG53 protein.

rhMG53 attenuated hepatic ischaemia/reperfusion injury via interaction with dysferlin. Rats were subjected to HIR or sham operation with or without administration of rhMG53 via caudal vein and then samples were collected after liver reperfusion for 6 and 24 hrs. ( A and B ) Immunofluorescence staining (×400) of liver dysferlin (DYSF) (Red) and nucleus (blue) and density analysis; ( C ) Western blot assay on liver dysferlin and MG53 at 6 hrs after reperfusion. ( D ) Immunoprecipitation assay of dysferlin/MG53 at 6 hrs after reperfusion. Date are mean ± SEM, n = 8/group, * P < 0.05, ** P < 0.01. HIR, hepatic ischaemia/reperfusion; rhMG53, recombinant human MG53 protein.

Not For Human Consumption!

Inquiry

  • Reviews (0)
  • Q&As (0)

Customer Reviews

Write a review

Ask a Question for All TRIM72 Products

Required fields are marked with *

My Review for All TRIM72 Products

Required fields are marked with *

0
cart-icon